- Thermo Fisher Scientific has been selected by Dr. Park CDMO in South Korea to supply advanced bioreactors and consumables for its new viral vector facility.
- The site, inaugurated in August 2025, is targeting cGMP certification in 2026 and will initially support 5,000 L AAV-based production per batch.
Thermo Fisher Scientific Inc. has announced a collaboration with Dr. Park, an emerging viral vector contract development and manufacturing organisation (CDMO) in South Korea. The company has selected Thermo Fisher to provide advanced bioreactors and consumables for its newest facility, inaugurated on 5 August 2025.
Dr. Park specialises in adeno-associated virus (AAV)-based viral vector production. Its new Phase 1 site is designed to achieve cGMP certification in 2026 and currently supports 5,000 litre production per batch, enabling up to 40 clinical-grade batches annually. Plans are in place to scale capacity further to 10,000 litres per batch.
The facility incorporates Thermo Fisher’s technologies, including the HyPerforma 1,000 L Single-Use Bioreactor, Nunc Automated Cell Factory Manipulator and DynaSpin Single-Use Centrifuge. These solutions aim to streamline processes, reduce manual interventions, and support efficient scale-up from clinical to commercial production.
“We are proud to collaborate with Dr. Park CDMO as they advance viral vector manufacturing in South Korea.”
Daniella Cramp, Senior Vice President and President, BioProduction at Thermo Fisher Scientific
